Trial Profile
A phase III study to compare the efficacy and safety of CHS-1420 versus Humira in subjects with rheumatoid arthritis
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 23 Jan 2015
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Coherus Biosciences
- 23 Jan 2015 New trial record
- 15 Dec 2014 Coherus BioSciences plans to initiate this study during the first half of 2015 to support the planned filing of a marketing application in the USA in 2016 and the EU in 2017, according to Coherus BioSciences SEC filing report 10-Q 2014.